Loading
Ovarian Cancer Diagnosis and Treatment / Nanoplatforms for Cancer Theranostics · Journal article
Journal of Ovarian Research · August 12, 2026
Raises a question worth testing. It does not answer one.
This review summarizes the development and potential of fluorescent probe–based imaging for ovarian cancer diagnosis, surgical navigation, and treatment monitoring. The field is emerging, with probes targeting FR, EGFR, γ-GGT, GnRHR, and β-Gal activity, but the source emphasizes that rigorous clinical validation, standardized trials, and integration of nanotechnology are required before clinical application.
Journal article. Patients with ovarian cancer (described in context of diagnosis, surgical navigation, and treatment monitoring).
Fluorescent probes can visualize small peritoneal implants, micrometastases, and tumor margins difficult to identify under white-light observation. Probe systems targeting ovarian cancer–associated biomarkers FR, EGFR, γ-GGT, GnRHR, and β-Gal activity have been developed. Some platforms incorporate activatable fluorescence, photothermal effects, or drug-loading capacity for image-guided surgery and targeted therapy.
No quantitative efficacy, safety, or diagnostic performance data reported.
This review identifies fluorescent probe technology as a potentially valuable tool for improving detection of small tumoral lesions and supporting complete cytoreductive surgery, but emphasizes that clinical professionals should await rigorous validation studies before adopting these approaches into routine practice.
This is a narrative review of emerging fluorescent probe technologies for ovarian cancer diagnosis and surgery, raising mechanistic and translational questions rather than reporting empirical trial results or clinical outcomes.
This review identifies fluorescent probe technology as a potentially valuable tool for improving detection of small tumoral lesions and supporting complete cytoreductive surgery, but emphasizes that clinical professionals should await rigorous validation studies before adopting these approaches into routine practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Ovarian cancer remains a major challenge among gynecologic malignancies because it often develops with vague or nonspecific symptoms and frequently disseminates within the peritoneal cavity before detection. Currently, no screening strategy has been proven to effectively reduce mortality in the general population, so many patients are diagnosed at an advanced stage. Therefore, improving diagnostic accuracy and treatment precision is important for better clinical outcomes. Fluorescent probe–based imaging has gained increasing attention in ovarian cancer diagnosis, surgical navigation, and treatment monitoring. Owing to their molecular targeting ability, these probes can help visualize small peritoneal implants, micrometastases, and tumor margins that may be difficult to identify under conventional white-light observation. This may improve lesion detection and support more complete cytoreductive surgery. In addition, some probe systems are being investigated for drug-delivery tracking and theranostic applications, combining imaging with therapeutic functions. In recent years, probes targeting ovarian cancer–associated biomarkers such as folate receptor(FR), epidermal growth factor receptor(EGFR), γ-glutamyl transpeptidase(γ-GGT), gonadotropin-releasing hormone receptor(GnRHR), and β-galactosidase(β-Gal) activity have been developed. Some of these platforms incorporate activatable fluorescence, photothermal effects, or drug-loading capacity, providing potential strategies for image-guided surgery and targeted therapy. However, several limitations remain. Conventional fluorescent dyes may have limited tissue penetration, photobleaching, background autofluorescence, and dependence on specialized imaging equipment. Off-target accumulation or biomarker expression in normal tissues can also reduce tumor-to-background contrast. Future studies should integrate nanotechnology, chemical probe design, and genetic engineering to improve penetration depth, signal stability, and tumor specificity. Before clinical application, these probes require rigorous validation in standardized trials to assess their safety, reproducibility, imaging performance, and therapeutic value.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.